For the latest updates on Gilead’s ongoing response to COVID-19, please click here.

Our Pipeline

Pipeline icon

Leading the Way in Cell Therapy

Our pipeline of cancer therapies in the areas of cell therapy, immuno-oncology, and targeted therapies includes investigational therapies and next-generation technologies that have the power to transform the way cancer is treated. As we look to the future, we remain focused on advancing technologies that could someday address additional hematological malignancies and solid tumors.

PROGRAM

PHASE

  • PHASE 1
  • PHASE 2
  • PHASE 3
  • FILED

Yescarta® (axi-cel)1

  • PHASE 3

Trial:

ZUMA-22

 

2L+ high-risk follicular lymphoma

Yescarta® (axi-cel)1

  • PHASE 3

Trial:

ZUMA-23

 

1L high-risk large B-cell lymphoma

Yescarta® (axi-cel)1

  • PHASE 2

Trial:

ZUMA-24

 

2L large B-cell lymphoma Outpatient

Yescarta® (axi-cel)

  • PHASE 2

Trial:

ZUMA-12

 

1L Diffuse large B cell lymphoma

Brexu-cel

  • PHASE 2

Trial:

ZUMA-4

 

Pediatric acute lymphocytic leukemia

Brexu-cel1

  • PHASE 2

Trial:

ZUMA-25

 

Basket (rare B-cell malignancies)

KITE-222 (CLL-1)

  • PHASE 1

Trial:

KITE-222

 

Relapsed/refractory acute myeloid leukemia

KITE-363 (CD19/20 bicistronic)

  • PHASE 1

Trial:

KITE-363

 

3L+ large B-cell lymphoma

1Publicly announced planned program (non-exhaustive).

Axi-cel - Axicabtagene ciloleucel.
Brexu-cel - Brexucabtagene autoleucel.

The safety and efficacy of these investigational agents or investigational uses of marketed products have not been established. These uses have not been approved by the US Food and Drug Administration or other regulatory authorities. There is no guarantee that these therapies or uses will be commercialized.

Some of the content on this page is not intended for users outside the US.